Abliva AB (publ) develops medicines for the treatment of primary mitochondrial diseases. The company is developing KL1333 that is in Phase 2/3 clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT that is in Phase 1b/2a clinical study for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.
Show more...
首席执行官
Dr. Ellen K. Donnelly Ph.D.
员工
6
国家
SE
上市
0 Comments
分享你的想法
FAQ
ABLIVA AB 今天的股价是多少?▼
NEVPF 当前价格为 $0.03 USD,过去 24 小时上涨了 +0%。在图表上更密切关注 ABLIVA AB 股价表现。
ABLIVA AB 的股票代码是什么?▼
根据交易所不同,股票代码可能会有所不同。例如,在 交易所,ABLIVA AB 的股票以代码 NEVPF 进行交易。